The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer

Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies when used as monotherapy. The assessment of Program Death Ligand-1 (PD-L1) tumor expression by immunohistochemistry...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaderbhaï, Courèche, Tharin, Zoé, Ghiringhelli, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406957/
https://www.ncbi.nlm.nih.gov/pubmed/30744168
http://dx.doi.org/10.3390/cancers11020201

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406957/
https://www.ncbi.nlm.nih.gov/pubmed/30744168
http://dx.doi.org/10.3390/cancers11020201

Ejemplares similares